Aripiprazole/Sertraline Hydrochloride

้˜ฟ็ซ‹ๅ“Œๅ”‘/็›้…ธ่ˆๆ›ฒๆž—

Report date: 2023/09/15 16:16:24

Base Information

Drug NameAripiprazole/Sertraline Hydrochloride
Drug Alias Name็›้…ธ่ˆๆ›ฒๆž—+้˜ฟ็ซ‹ๅ“Œๅ”‘Aripiprazole-SertralineAripiprazole+Sertraline Hydrochloride้˜ฟ็ซ‹ๅ“Œๅ”‘็›้…ธ่ˆๆ›ฒๆž—Aripiprazole-Sertraline mixt +[11]ย 
ClassificationSmall molecules
Mechanisms of ActionDopamine D3 receptor agonistsSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor agonists +[5]ย 
TargetsSerotonin 2a (5-HT2a) receptorSerotonin 1a (5-HT1a) receptorDopamine D2 receptor +[5]ย 
Therapy Area/IndicationsDepressive Disorder, Major
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanAustraliaSouth Korea +[5]ย 
CombinationsYes Sertraline HydrochlorideAripiprazole
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOtsuka Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, Major

Other Information

ATC CodeN/A
Related LinksWikipedia